Rhythm Pharmaceuticals (RYTM)
(Real Time Quote from BATS)
$88.79 USD
-1.45 (-1.61%)
Updated Aug 5, 2025 12:12 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RYTM 88.79 -1.45(-1.61%)
Will RYTM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RYTM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RYTM
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
RYTM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q2 Earnings Expected to Decline
RYTM Stock Rises on Upbeat Acquired Hypothalamic Obesity Study Data
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates
Other News for RYTM
Rhythm (RYTM) Forecasts 2025 Non-GAAP Operating Expenses
Rhythm Pharmaceuticals (RYTM) Kicks Off Next Phase of RM-718 Trial
Rhythm Pharmaceuticals (RYTM) Sets 2025-2026 Milestones for Setmelanotide Trials
Rhythm Pharmaceuticals (RYTM) Surpasses Revenue Expectations in Q2
Rhythm Pharmaceuticals GAAP EPS of -$0.75 misses by $0.09